These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt, with results 2017-003851-45 A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102 2019-02-27 not-yet-due
Listed as ongoing, but also has a completion date 2018-003163-67 An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I Deficiency 2022-12-15 bad-data
Listed as ongoing, but also has a completion date 2018-004837-34 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adu... 2023-01-27 bad-data
Exempt 2019-004791-19 A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177 not-yet-due
Other 2022-003722-45 A Phase 3 Open-Label Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects with Arginase 1 Deficiency Studio in aperto di fase 3 sulla sicurezza di pegzilarginase per via sottocutanea s... not-yet-due